Development of Claudin MAbs for Treating Solid Tumors
用于治疗实体瘤的 Claudin MAb 的开发
基本信息
- 批准号:10631161
- 负责人:
- 金额:$ 70.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-01 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:AbbreviationsAddressAdverse effectsAffinityAmericanAmino AcidsAntibodiesBindingBiological AssayBiopsyBiosensorCD3 AntigensCD34 geneCancer cell lineCell modelCessation of lifeClinicClinicalDataDevelopmentDrug KineticsEndometrial CarcinomaEngineeringExhibitsFailureFamily memberFundingFutureHumanIn VitroIntegral Membrane ProteinIsoelectric PointLeadMalignant neoplasm of lungMalignant neoplasm of ovaryMalignant neoplasm of pancreasMalignant neoplasm of testisMass Spectrum AnalysisMediatingMembraneMembrane ProteinsModelingMonoclonal AntibodiesMusPatientsPeripheral Blood Mononuclear CellPersonsPharmaceutical PreparationsProteinsProteomePublic HealthRiskRisk AssessmentSafetySmall Business Innovation Research GrantSolid NeoplasmSpecificityT cell infiltrationT-Cell ActivationT-Cell ProliferationT-LymphocyteTemperatureTestingTherapeuticTherapeutic Monoclonal AntibodiesTight JunctionsTimeTissuesToxic effectTumor VolumeViscosityWorkXenograft ModelXenograft procedurebiopharmaceutical industrycancer cellcancer typecandidate selectioncell killingclaudin 6clinical developmentclinical efficacycytokinecytokine release syndromedifferential expressioneffective therapyefficacy testingexperimental studyextracellularhuman diseasehumanized mousein vivolight scatteringmalignant stomach neoplasmmanufacturemeltingneoplastic cellovarian neoplasmoverexpressionpre-clinicalstem cellstherapeutic targettherapeutically effectivetimelinetumor
项目摘要
ABSTRACT
Solid tumors lead to 580,000 deaths annually in the US, and safe and effective therapeutics for many late-
stage solid tumors are lacking. Ovarian cancer alone kills 14,000 people each year, and many patients do not
respond to currently available treatments. The tight junction protein Claudin 6 (CLDN6) is a validated
therapeutic target for many solid tumor types, including ovarian, endometrial, testicular, gastric, and pancreatic
cancer. CLDN6 is differentially expressed on cancer cells with almost no expression in normal, healthy tissue.
Despite being an attractive target, therapeutic MAbs targeting CLDN6 are difficult to discover due to an
absolute need for high specificity. There are 26 human CLDN family members in total and most are broadly
expressed and highly conserved, making drug specificity when targeting the CLDNs critically important but
especially challenging. The extracellular region of CLDN6 closely resemble the widely expressed CLDN9 (3
amino acids different). The few CLDN6 MAbs discovered by others have demonstrated significant binding to
other CLDN family members and most have now been halted in development. Here, we will develop a CLDN6
therapeutic for solid tumors.
摘要
在美国,实体瘤每年导致580,000人死亡,而对于许多晚期肿瘤,
阶段性实体瘤缺乏。仅卵巢癌每年就导致14,000人死亡,许多患者没有
对目前可用的治疗方法作出反应。紧密连接蛋白Claudin 6(CLDN6)是一种经过验证的
许多实体瘤类型的治疗靶点,包括卵巢、子宫内膜、睾丸、胃和胰腺
癌CLDN6在癌细胞上差异表达,在正常健康组织中几乎不表达。
尽管是一个有吸引力的靶标,但由于CLDN6的免疫缺陷,靶向CLDN6的治疗性MAb难以发现。
绝对需要高特异性。总共有26个人CLDN家族成员,并且大多数广泛分布于
表达和高度保守,使得靶向CLDN时的药物特异性至关重要,
特别具有挑战性。CLDN6的胞外区与广泛表达的CLDN9非常相似(3
氨基酸不同)。由其他人发现的少数CLDN6 MAb已经证明与CLDN6的显著结合。
其他CLDN家族成员和大多数现在已经停止发展。在这里,我们将开发一个CLDN6
用于实体瘤的治疗剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSEPH Benjamin RUCKER其他文献
JOSEPH Benjamin RUCKER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSEPH Benjamin RUCKER', 18)}}的其他基金
Development of Claudin MAbs for Treating Solid Tumors
用于治疗实体瘤的 Claudin MAb 的开发
- 批准号:
10482193 - 财政年份:2022
- 资助金额:
$ 70.93万 - 项目类别:
Development of Nav1.7 Monoclonal Antibodies for Treating Pain
开发用于治疗疼痛的 Nav1.7 单克隆抗体
- 批准号:
10318547 - 财政年份:2021
- 资助金额:
$ 70.93万 - 项目类别:
Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders
开发针对 TEM 细胞的 Kv1.3 单克隆抗体用于治疗自身免疫性疾病
- 批准号:
10374043 - 财政年份:2014
- 资助金额:
$ 70.93万 - 项目类别:
Development of High-expressing Ion Channels for Research and Therapeutic Applicat
用于研究和治疗应用的高表达离子通道的开发
- 批准号:
8775955 - 财政年份:2014
- 资助金额:
$ 70.93万 - 项目类别:
Development of High-expressing Ion Channels for Research and Therapeutic Applicat
用于研究和治疗应用的高表达离子通道的开发
- 批准号:
8920157 - 财政年份:2014
- 资助金额:
$ 70.93万 - 项目类别:
Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders
开发针对 TEM 细胞的 Kv1.3 单克隆抗体用于治疗自身免疫性疾病
- 批准号:
9906631 - 财政年份:2014
- 资助金额:
$ 70.93万 - 项目类别:
Isolation of Monoclonal Antibodies against Membrane Proteins
膜蛋白单克隆抗体的分离
- 批准号:
8057198 - 财政年份:2011
- 资助金额:
$ 70.93万 - 项目类别:
Development of P2X3 Ion Channel MAbs for the Treatment of Pain
开发用于治疗疼痛的 P2X3 离子通道单克隆抗体
- 批准号:
9130898 - 财政年份:2011
- 资助金额:
$ 70.93万 - 项目类别:
Isolation of Monoclonal Antibodies against Membrane Proteins
膜蛋白单克隆抗体的分离
- 批准号:
8215713 - 财政年份:2011
- 资助金额:
$ 70.93万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 70.93万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 70.93万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 70.93万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 70.93万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 70.93万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 70.93万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 70.93万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 70.93万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 70.93万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 70.93万 - 项目类别:
Research Grant